Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis
Importance: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5-DM) is associated with rapid progression and high early mortality, but long-term outcomes beyond the early high-risk phase remain poorly characterized. Objective: To evaluate the attainability, associated factors, and durability of low disease activity (LDA) and drug-free remission (DFR) in patients with MDA5-DM. Design, Setting, and Participants: This retrospective cohort study at a tertiary referral center in China included consecutive patients with MDA5-DM who were enrolled between August 2003 and July 2023 and followed up through August 2025. Median follow-up was 5.7 (IQR, 3.4-7.4) years. The data were analyzed from September 2025 through December 2025. Exposures: Baseline demographic, clinical, and laboratory characteristics. Main Outcomes and Measures: Primary outcomes were experiencing LDA and DFR. Secondary outcomes included relapse after LDA or DFR and patient-reported outcomes assessed using the Patient Global Assessment and Health Assessment Questionnaire Disability Index. Results: Of 561 screened patients, 523 (93.2%) were included. Among 523 patients with MDA5-DM, 345 (65.9%) were female, 178 (34.1%) were male, and the median age at disease onset was 50.0 years (IQR, 41.0-57.5 years). Interstitial lung disease was present in 488 patients (93.3%) at baseline. Cumulative 1-, 3-, 5-, and 10-year all-cause mortality was 28.1%, 30.5%, 30.8%, and 31.7%, respectively. The 1-, 3-, 5-, and 10-year cumulative incidences of LDA were 3.1%, 47.1%, 59.0%, and 66.8%, respectively; corresponding incidences of DFR were 0%, 5.0%, 15.1%, and 31.0%, respectively. The median time from enrollment was 23 months (IQR, 18-34) for LDA and 46 months (IQR, 37-67) for DFR. Respiratory failure was associated with lower rates of LDA (subdistribution hazard ratio [sHR], 0.31; 95% CI, 0.19-0.51) and DFR (sHR, 0.33; 95% CI, 0.12-0.87), whereas a higher CD8-positive T-cell count was associated with higher rates of LDA (sHR, 1.15; 95% CI, 1.08-1.22) and DFR (sHR, 1.19; 95% CI, 1.09-1.31). The 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR. LDA and DFR were associated with lower Patient Global Assessment and Health Assessment Questionnaire Disability Index scores compared with non-LDA or non-DFR states. Conclusions and Relevance: The findings of this cohort study suggest that LDA was an attainable and durable long-term outcome for many patients with MDA5-DM, whereas DFR occurred less frequently. These findings may inform long-term disease control targets and treatment expectations in MDA5-DM.
Authors
- Chen Zong (ORCID: https://orcid.org/0009-0007-0695-033X)
- Yongpeng Ge (ORCID: https://orcid.org/0000-0003-3674-9307)
- Longyang Zhu (ORCID: https://orcid.org/0000-0001-8116-0361)
- Qinglin Peng (ORCID: https://orcid.org/0000-0002-1271-1729)
- Yiran Chen (ORCID: https://orcid.org/0000-0003-2261-7100)
- Linrong He (ORCID: https://orcid.org/0000-0002-9044-9340)
- Xiaoming Shu (ORCID: https://orcid.org/0000-0001-5425-6157)
- Guochun Wang (ORCID: https://orcid.org/0000-0001-7499-6881)
- Chunjia Li (ORCID: https://orcid.org/0000-0003-0647-3039)
- Xiaolan Tian (ORCID: https://orcid.org/0009-0005-7437-0201)
- Xinyue Xiao
- Qi Pan (ORCID: https://orcid.org/0009-0001-6221-8924)
- Lin Liang
- Sizhao Li
- Xia Liu
- Xiaoqin Luo
- Shanshan Li
- Yunfeng Dai
- Xin Lu
- Wei Jiang
- Lu Zhang
- Fang Chen
- Hanbo Yang
- Lin Luo
- Huihui Ji
- Xinxin Zhang
- ying li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- China-Japan Friendship Hospital (CN)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1001/jamadermatol.2026.4776
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00